Ongoing trials are assessing the combination of immunotherapy and PI3K/AKT/mTOR pathway inhibitors in PTEN-mutant endometrial cancers, including poorly differentiated EC subtypes. The gene discussed is PIK3CA; the disease is endometrial cancer.